U0126: Not only a MAPK kinase inhibitor

Yijie You; Yunlian Niu; Jian Zhang; Sheng Huang; Peiyuan Ding; Fengbing Sun; Xuhui Wang

doi:10.3389/fphar.2022.927083

U0126: Not only a MAPK kinase inhibitor

Front Pharmacol. 2022 Aug 25:13:927083. doi: 10.3389/fphar.2022.927083. eCollection 2022.

Authors

Yijie You¹, Yunlian Niu², Jian Zhang¹, Sheng Huang¹, Peiyuan Ding¹, Fengbing Sun¹, Xuhui Wang^{1

3}

Affiliations

¹ Department of Neurosurgery, Xinhua Hospital Chongming Branch, Shanghai, China.
² Department of Neurology, Xinhua Hospital Chongming Branch, Shanghai, China.
³ Department of Neurosurgery, Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine, The Cranial Nerve Disease Center of Shanghai JiaoTong University, Shanghai, China.

Abstract

U0126, as an inhibitor of the MAPK signaling pathway, is closely related to various biological processes, such as differentiation, cell growth, autophagy, apoptosis, and stress responses. It makes U0126 play an essential role in balancing cellular homeostasis. Although U0126 has been suggested to inhibit various cancers, its complete mechanisms have not been clarified in cancers. This review summarized the most recent and relevant research on the many applications of U0126 and described its role and mechanisms in different cancer cell types. Moreover, some acknowledged functions of U0126 researched in the laboratory were listed in our review. We discussed the probability of using U0126 to restain cancers or suppress the MAPK pathway as a novel way of cancer treatment.

Keywords: MAPK inhibitors; MAPK signal pathway; U0126; cancer; cancer therapy.

Publication types

Review